First-line, FDA-cleared CBT for insomnia & anxiety

Enhance clinical practice by offering patients instant access to FDA-cleared digital treatment with SleepioRx and DaylightRx.

Request Demo

FDA-Cleared

500K+ Patients

Treated & supported

App Store Rating

Vetted & Secure

HIPAA compliant &
HITRUST certified

Reimbursable

by Insurance

Fully digital, first-line, cognitive-behavioral therapy (CBT) for patients

Immediate access to evidence-based care for patients

Get patients instant access to cognitive behavioral therapy (CBT), the gold-standard treatment for insomnia disorder¹

Expanded, reimbursable care options for clinicians

Address high patient demand and long waitlists with reimbursable, FDA-cleared digital mental health treatments

Scalable mental health care for systems & practices

Grow your practice by expanding services and increasing patient volume without overburdening clinicians

Explore Use Cases

Read FAQs

insurance-reimbursable digital treatments

Sleepio RX

Proven to help 76% of insomnia patients achieve clinical improvement with no serious side effects³

Daylight RX

Proven to help 71%
of anxiety patients achieve clinical improvement with no serious side effects⁴

Expand access and close care gaps

Clinical use cases for FDA-cleared treatments

First-line care

SleepioRx + DaylightRx provide first-line recommended treatment for insomnia & anxiety

PCPs, Psychiatrists, Sleep med

Waitlist support

SleepioRx + DaylightRx provide support for patients on long waitlists

Therapists, Psychiatrists, Sleep med

Therapy reinforcement

SleepioRx + DaylightRx reinforce therapy skills and support practice of CBT between sessions

Therapists, Sleep med

Rx combination
or discontinuation

In combo with meds, SleepioRx + DaylightRx improve outcomes or support discontinuation

PCPs, Psychiatrists, Sleep med

Comorbid condition
treatment

SleepioRx + DaylightRx reinforce therapy skills and support practice of CBT between sessions

Therapists, Psychiatrists

Maintenance support

Offered ahead of treatment termination, SleepioRx + DaylightRx help maintain CBT skills

Therapists, Psychiatrists, Sleep med

Request Demo

SUPPORT CLINICAL PRACTICE

Trusted, clinically proven care

Read the Research

100+

Peer-reviewed publications demonstrating safety + efficacy

70%+

Combined  improvement rate³,⁴,⁵

References in clinical guidelines like the American College of Physicians¹

What are SleepioRx and DaylightRx?

SleepioRx¹ and DaylightRx² are FDA-cleared digital treatments for insomnia disorder and generalized anxiety disorder, respectively, delivering guideline-recommended cognitive behavioral therapy (CBT) through video and audio lessons in mobile apps. Designed by sleep and anxiety experts, the treatments help patients understand unhealthy patterns and address the thoughts and behaviors that sustain insomnia and anxiety. CBT techniques delivered in an engaging and interactive format help patients overcome insomnia and anxiety, quickly.

^{1. SleepioRx is a digital therapeutic intended for the treatment of chronic insomnia/insomnia disorder as an adjunct to usual care in patients aged 18 and older. SleepioRx is a prescription device delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) and can be made available on the order of a licensed healthcare provider. Patients should read the instructions for use for full information.
2. DaylightRx is a prescription device delivering Cognitive Behavioral Therapy and can be made available on the order of a licensed healthcare provider. DaylightRx is a digital therapeutic intended to treat generalized anxiety disorder (GAD) by improving a patient's GAD symptoms as an adjunct to usual care in patients aged 22 years and older. Patients should read the instructions for use for full information.}

What evidence is there showing that SleepioRx and DaylightRx work?

Which insurers cover SleepioRx and DaylightRx?

What types of providers can authorize use of these products and bill for reimbursement?

What are SleepioRx and DaylightRx?

Ready to offer patients FDA-cleared treatments?

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

1. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. doi: 10.7326/M15-2175. Epub 2016 May 3. PMID: 27136449

2. DeGeorge KC, Grover M, Streeter GS. Generalized Anxiety Disorder and Panic Disorder in Adults. Am Fam Physician. 2022 Aug;106(2):157-164. PMID: 35977134.

3. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769–781.4. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A. J., Emsley, R., Gu, J., Shin, O., Otto, M. W., Craske, M. G., Saunders, K. E. A., Goodwin, G. M., & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168–1178. https://doi.org/10.1002/da.23079

5. Internal Data, compared to network averages, Nov 2023.

6. Internal Data, observed in independently conducted HEOR study of digital program in an employer population, May 2020.

7. Unpublished RCT data, Dec 2023. Stat reflects a 25% improvement in scores on a validated screening measure. Screening tools alone are not sufficient to diagnose depression.

Sleepio, Daylight, and Spark Direct are digital programs that may help individuals live well with mental health conditions and symptoms by providing them with cognitive and behavioral techniques that can improve sleep, feelings of worry and anxiety, and mood, respectively. Sleepio, Daylight, and Spark Direct have not been reviewed or approved by the Food & Drug Administration and are not intended to diagnose or treat any medical condition. Please read the instructions for use.

DOC-XXXX Effective May 2025